If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
104
results.
Updated on
24/10/2026 [09:02:00]
Results 25 to 50 of 104
Absstract of: US2016060335A1
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
Absstract of: WO2020141608A1
The purpose of the present invention is to provide a test method and the like that is specific for ulcerative colitis and for primary sclerosing cholangitis. The present invention firstly provides a test method for ulcerative colitis, the test method being a detection step of detecting, in a sample and as an indicator of ulcerative colitis, an antibody that immunologically reacts with integrin αVβ6 and/or an antibody that immunologically reacts with integrin αVβ3. The present invention secondly provides a test method for primary sclerosing cholangitis, the test method being a detection step of detecting, in a sample and as an indicator of primary sclerosing cholangitis, an antibody that immunologically reacts with an antibody that immunologically reacts with integrin αVβ6 and/or integrin αVβ3.
Absstract of: WO2026182113A1
A method for predicting endoscopic activity of ulcerative colitis, the method comprising: step (a) for measuring the concentration of one or more substances selected from the group consisting of C9, CYTF, LBP, Gelsolin, a1-Microglobulin, Resistin, MMP-8, MMP-9, HPT, C4, IGFBP-2, C3, and BIN2 in a blood sample of a subject; and step (b) for determining endoscopic activity of ulcerative colitis in the subject on the basis of the concentration of the protein in the blood sample measured in step (a).
Absstract of: MX2025013570A
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Absstract of: WO2026178656A1
It is provided a biodegradable gel mimetic matrix for cells seeding, the mimetic matrix composed of a functionalized alginate and a functionalized biodegradable polymer with at least one peptide, such as PEG. The PEG carries vinyl-sulfone groups that enable it to interact with the peptides and alginate. Alginate controls the gelation and stiffness of the mimetic matrix. It is further provided a method of culturing cells onto the matrix, providing a model to study epithelial cell behaviour toward a pathological state like inflammatory bowel disease (IBD) or cancer, like colorectal cancer.
Absstract of: WO2025120137A1
The present invention relates to the field of mucins and mRNA isoforms thereof, more in particular the use of mucins and mRNA isoforms in subjects suspected having an intestinal disorder. Provided herein is an in vitro method for determining the presence of barrier damage to the intestinal tract and/or prediction of therapy response and recovery thereto by determining the expression of at least 3 mRNA isoforms originating from genes selected from the list comprising: MUC1, MUC2, MUC3A, MUC4, MUC5AC, MUC5B, MUC6, MUC12, MUC12-AS1, MUC13, MUC16, MUC17, MUC19, MUC20 or an overlapping transcript or a pseudogene thereof.
Absstract of: CN122643332A
The invention relates to the technical field of IBS-D humanized models, and particularly discloses a construction method of a cold syndrome IBS-D humanized animal model, the model and application. The construction method comprises the following steps: screening IBS-D patients which meet Rome IV diagnostic standards and are dialectically cold in traditional Chinese medicine as coprophilous fungus donors, collecting fresh feces of the donors, and preparing coprophilous fungus suspension; transplanting the prepared coprophilous fungus suspension into the body of a sterile mouse through an intragastric administration way, and carrying out periodic field planting; after colonization is finished, the IBS-D disease phenotype and the traditional Chinese medicine cold syndrome phenotype of the receptor mouse are detected, and if the receptor mouse has the IBS-D disease phenotype and the traditional Chinese medicine cold syndrome phenotype at the same time, it is judged that the cold syndrome IBS-D humanized animal model is successfully constructed. According to the method, the flora-syndrome correlation model is created for the first time, the clinical simulation degree is high, a new mechanism research normal form is provided, a standardized modeling system is constructed, repeatability and stability are excellent, the drug evaluation dimension is expanded, and precise drug use is promoted.
Absstract of: CN122648564A
The invention belongs to the field of medical detection, and particularly relates to a detection kit for predicting response of ulcerative colitis patients to vializumab treatment, application of reagents in preparation of the kit and an integrated detection system.The kit comprises the reagents used for detecting expression levels of genes TMEM273, HSF1, SLC25A17 and STT3A in a subject sample; the expression levels of the four genes are used for predicting and evaluating whether the patient responds to vializumab. The invention has high specificity on alpha4beta7-targeted vializumab, and has no prediction efficiency on beta7-targeted etrazumab, thereby proving the non-pan inflammation index and high targeting accuracy of the etrazumab. According to the method, the crossing of liquid biopsy can be realized: the histological model shows obvious prediction efficiency in an independent peripheral blood queue, the technical bottleneck that the local immune genes of the intestinal tract cannot be detected through blood drawing is broken through, and the detection threshold and the pain of a patient are greatly reduced.
Absstract of: CN122643287A
The invention discloses an application of luteolin in preparation of a targeted ANGPTL4 medicine for treating colorectal cancer, particularly provides a comprehensive single cell resolution map for tumor microenvironment (TME) remodeling in the progress process of inflammatory bowel disease (IBD) related colorectal cancer (CRC), and discloses a multi-aspect anti-tumor effect of the luteolin. Including direct inhibition of tumors, normalizing TME, and inhibition of oncogenic secretory factor angiopoietin-like protein 4 (ANGPTL4). The ANGPTL4 is further identified as a luteolin response biomarker with functional significance in CRC pathogenesis, and a new way is opened up for risk stratification, treatment monitoring and potential targeted intervention.
Absstract of: US20260250768A1
The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a truncated human Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) protein. The disclosure also provides isolated and recombinant human SIGIRR protein variants that comprise a truncation at a position corresponding to position 215. The truncation, and the nucleic acid molecules encoding this change, associate with early-onset inflammatory bowel disease (EO-IBD). The disclosure also provides methods for determining whether a subject has or has a risk of developing EO-IBD, based on the identification of such alterations in the nucleic acid molecules encoding SIGIRR.
Absstract of: US20260250767A1
The present disclosure generally relates to the treatment of subjects having IBD or at risk of developing IBD by administering an Indoleamine 2,3-Dioxygenase 2 (IDO2) agonist or a SMAD Family Member 2 (SMAD2) agonist to the subject.
Absstract of: WO2025085674A1
In one aspect, the present disclosure provides a method for selecting a subject having ulcerative colitis for treatment with ADS051, or a pharmaceutically acceptable salt thereof, the method comprising: (a) measuring MRP2 seRNA in a stool sample obtained from the subject; and (b) selecting the subject for treatment when the level of MRP2 seRNA in the stool sample exceeds a threshold value. In some embodiments, the subject has moderate or severe ulcerative colitis.
Absstract of: WO2025085928A1
This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.
Absstract of: CN122628157A
本发明涉及一种与皮质醇小分子特异性结合的人工从头设计蛋白，所述蛋白质的氨基酸序列如SEQ ID NO:1所示。本发明通过深度学习方法，针对皮质醇分子的空间结构、疏水特征以及官能团分布，使用模型构建与其匹配的结合口袋，使设计蛋白能够通过疏水相互作用、氢键作用及空间构象互补等方式与皮质醇形成稳定结合。相比天然蛋白随机筛选方式，本发明可通过结构约束提高结合位点与目标分子的匹配程度，从而提升对皮质醇的识别特异性。
Absstract of: CN122631891A
0001 本发明公开了一种用于区分结直肠癌与结直肠腺瘤的标志物及其应用，涉及生物医学技术领域，标志物选自以下任一项：由SELL、CD177、ITGAL、OLR1、B2M、LAG3组成的外泌体表面驱动标志物；由TGM3、PSMB4、KRT80、KRT2、DSG1、CPOX、CPN1、SUB1、LSM2、RAB34、PZP、SERPINA5、HYDIN、PGLYRP1组成的内部核心蛋白；KRT80单指标标志物。本发明能够实现结直肠癌与结直肠腺瘤的检测。
Absstract of: CN122629194A
0001 本发明公开了一种间充质基质细胞治疗克罗恩病的肠道微生物标志物、产品及其应用，本发明提供的肠道微生物标志物包括丹毒丝菌目、粪杆菌属、丹毒丝菌科、芽孢杆菌纲、乳杆菌目、乳杆菌科、紧密乳杆菌属、厚壁菌门、鼠杆菌科、拟杆菌目、拟杆菌纲、拟杆菌门、梭菌纲、毛螺菌目、毛螺菌科、梭菌纲UCG‑014、颤螺菌目中的一种或多种。通过检测上述标志物的含量或丰度，可预测间充质基质细胞治疗克罗恩病的疗效。本发明还提供了基于上述标志物构建疗效预测模型的方法，得到疗效预测模型。本发明能够实现对间充质基质细胞治疗克罗恩病疗效的提前预测，具有良好的临床应用前景。
Absstract of: CN122612770A
The invention belongs to the technical field of biological detection, and relates to application of a urine metabolite composition in preparation of a product for detecting the curative effect of Crohn disease cells. The urine metabolite composition is prepared from prolyl-proline, 7, 8-dihydrobiopterin, tyrosyl-glycine and pyrogallic phenol-2-O-sulfate, and the urine metabolite composition is prepared from the following raw materials: prolyl-proline, 7, 8-dihydrobiopterin, tyrosyl-glycine and pyrogallic phenol-2-O Experiments find that the combination of the urine metabolites can be used for evaluating the curative effect of cells, especially the curative effect of mesenchymal stem cells on Crohn's disease, so that multi-time-point detection with high repeatability and convenience in operation can be realized by utilizing the characteristics of urine sample detection, and the curative effect of cells, especially the curative effect of mesenchymal stem cells on Crohn's disease, can be realized. Particularly, the change of the curative effect of the mesenchymal stromal cells for treating the Crohn disease is objectively and dynamically monitored.
Absstract of: AU2026213986A1
Provided herein are compositions and methods to that target microbial proteases to ameliorate the intestinal barrier dysfunction and restore mucosal integrity. They are useful to treat and prevent diseases and disorders caused by pathogenic bacteria in the gastrointestinal system of a subject. ug u g
Absstract of: US20260242441A1
Described herein are methods of reducing CD3-dependent T cell signaling in a subject in need thereof. Also described are method of increasing T-regulatory (Treg) cells, or decreasing T-helper 17 (Th17) cells. These methods involve administering butyrophilin A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2-related isoform, or a BTN2A2-related isoform fragment, or a conjugate or fusion polypeptide comprising any of the foregoing to the subject. These methods are beneficial for patients with autoimmune disorders and inflammatory disorders such as allergy, asthma, glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, an autoimmune or inflammatory neurological disease, antibody mediated transplant rejection, infantile cholestasis, haemophagocytic lymphohistiocytosis, erythrocytic haemophagocytosis, malnutrition, systemic lupus erythematosus (lupus), psoriasis, myasthenia gravis or HIV. Further described are fusion proteins having BTN2A2 and an Fc domain.
Absstract of: WO2026173915A1
Systems and methods for training machine learning models are described. The methods may comprise, e.g., receiving a first plurality of images of tissue specimens stained with a histochemical stain; receiving a second plurality of images of the tissue specimens stained with an immunohistochemical stain; aligning corresponding pairs of images; segmenting the aligned corresponding pairs of images to generate first and second pluralities of segmented images; mapping segments in each segmented image of the first plurality to corresponding segments in an image of the second plurality; and generating labeled image data by labeling segments in the images of the first plurality as exhibiting a specified cellular feature (or biomarker) based on detection of a signal associated with the immunohistochemical stain. In some instances, the labeled image data can be used to train a machine learning model for a digital pathology application, e.g., the evaluation of colitis severity.
Absstract of: US20260243763A1
In various embodiments methods of distinguishing Crohn's disease from ulcerative colitis are provided. In certain embodiments the methods comprise determining, or causing to be determined, the level of IgG antibodies that bind a malondialdehyde-acetaldehyde adduct (MAA adduct) in a biological sample from a mammal, where an elevated level of said antibodies as compared to the average level found in a mammal with Crohn's disease is an indicator that the mammal has ulcerative colitis rather than Crohn's disease
Absstract of: KR20260126133A
0001a 염증성 장질환(inflammatory bowel disease, IBD) 치료용 세포 치료제 약효 평가 방법 및 스크리닝 방법에 관한 것으로, 보다 상세하게는 인간 PBMC로 인간화한 IBD 동물에 세포 치료제를 투여하여 개선 효과를 확인하는 단계를 포함하는 IBD 치료용 세포 치료제 약효 평가 방법 및 스크리닝 방법에 관한 것이다. 본 발명에 따르면, 사람 유래 말초혈액 단핵세포(PBMC)를 이용하여 인간화된 동물모델에서 염증성 장질환(IBD)을 유도하고, 해당 모델에서 세포 치료제의 효능을 평가함으로써, 인간 특이적 면역 반응을 반영한 세포 치료제의 예방 또는 치료 효과를 보다 정밀하게 검증할 수 있다. 이에 따라, 종래의 일반적인 동물모델에서는 재현하기 어려웠던 인간 면역계 기반의 염증 반응 및 치료 반응을 효과적으로 평가할 수 있다.
Absstract of: CN122588232A
0001 本发明属于生物技术领域，尤其涉及克罗恩病肠系膜脂肪外泌体在评估克罗恩病肠道纤维化水平及构建克罗恩病肠道纤维化动物模型中的用途。miR‑184可作为克罗恩病伴发肠道纤维化的风险评估标志物，还可作为干预克罗恩病动物模型的工具以干预肠道纤维化等水平。NCOR2蛋白可作为克罗恩病伴发肠道纤维化的风险评估标志物，还可作为干预克罗恩病动物模型的工具以干预肠道纤维化等水平。本公开验证了基于上述两个靶点构建克罗恩病伴肠道纤维化实验模型方案的可行性，为深化克罗恩病相关研究，尤其是加深对克罗恩病继发肠道纤维化病理进程的认知提供了支撑。
Absstract of: CN122588228A
本发明属于生物医药技术领域，具体而言，涉及一种克罗恩病肠道纤维化标志物及应用。本发明公开了一种定量检测IL4I1表达水平的试剂或试剂盒在制备用于预后评估、诊断或监测克罗恩病肠道纤维化产品中的应用。本发明旨在揭示CD肠道纤维化发生的分子机制，并探究其靶向治疗策略，为临床上CD肠道纤维化的预防与治疗提供理论与实验基础。
Nº publicación: US20260234724A1 13/08/2026
Applicant:
GENEOSCOPY INC [US]
GENEOSCOPY, INC.
Absstract of: US20260234724A1
The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
BOPI
Electronic site
